The K-Ras ligand-Linker Conjugate 5 is primarily used in the field of cancer research and drug development. It is designed to target and inhibit the K-Ras protein, which is often mutated in various cancers, including pancreatic, lung, and colorectal cancers. This conjugate plays a crucial role in the development of targeted therapies by binding specifically to the K-Ras protein, thereby disrupting its function and preventing the growth and proliferation of cancer cells. Researchers utilize this compound to study the mechanisms of K-Ras signaling pathways and to evaluate the efficacy of potential anti-cancer drugs. Additionally, it serves as a valuable tool in the design and optimization of new therapeutic agents aimed at treating K-Ras-driven malignancies.